Search

Your search keyword '"Harrower T"' showing total 100 results

Search Constraints

Start Over You searched for: Author "Harrower T" Remove constraint Author: "Harrower T"
100 results on '"Harrower T"'

Search Results

1. Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom

2. AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis

4. Validating the portal population of the United Kingdom Multiple Sclerosis Register

6. Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months.

7. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin

9. Unilateral transplantation of human primary fetal tissue in four patients with huntington's disease: NEST-UK safety report ISRCTN no 36485475. (Paper)

10. How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

11. Identification of symbol digit modality test score extremes in Huntington's disease

15. Outcome of cell suspension allografts in a patient with\ud Huntington’s disease

18. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

19. Development and validation of Spasticity Index—Amyotrophic Lateral Sclerosis.

21. Discrepancies in reporting the CAG repeat lengths for Huntington's disease

23. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

24. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

25. Long term survival of porcine expanded neural precursors in the rat model of Parkinson's disease. (ABN Abstracts)

30. Gal is widely expressed in embryonic porcine stem cells and neural tissue

35. PWE-066 Clinical features of demyelination during anti-tnf therapy: preliminary outcomes of the pred4 study

38. Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)

39. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

40. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.

41. Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.

42. Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.

43. Measuring disability in multiple sclerosis: the WHODAS 2.0.

44. Quality assurance programs for vitamin A and E in serum: are we doing enough to assess laboratory performance?

45. Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12.

46. Measuring coping in multiple sclerosis: The Coping Index-MS.

47. The impact of smoking cessation on multiple sclerosis disease progression.

48. The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.

49. Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.

50. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment.

Catalog

Books, media, physical & digital resources